FPMI (FluoroPharma Medical) Operating Income: $-2.20 Mil (TTM As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Operating Income?

FluoroPharma Medical FPMI Operating Income is $-2.20 Mil as of Dec. 2016.

FluoroPharma Medical's Operating Income for the three months ended in Dec. 2016 was $-0.52 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2016 was $-2.20 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. FluoroPharma Medical's Operating Income for the three months ended in Dec. 2016 was $-0.52 Mil. FluoroPharma Medical's Revenue for the three months ended in Dec. 2016 was $0.00 Mil. Therefore, FluoroPharma Medical's Operating Margin % for the quarter that ended in Dec. 2016 was %.

FluoroPharma Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. FluoroPharma Medical's annualized ROC % for the quarter that ended in Dec. 2016 was -30.39%. FluoroPharma Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 3,450.00%.

FluoroPharma Medical  (OTCPK:FPMI) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

FluoroPharma Medical's annualized ROC % for the quarter that ended in Dec. 2016 is calculated as:

ROC % (Q: Dec. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2016 ) + Invested Capital (Q: Dec. 2016 ))/ count )
=-2.084 * ( 1 - 0% )/( (6.943 + 6.772)/ 2 )
=-2.084/6.8575
=-30.39 %

where

Invested Capital(Q: Sep. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.387 - 3.674 - ( 0.028 - max(0, 10.319 - 0.089+0.028))
=6.943

Invested Capital(Q: Dec. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.335 - 4.029 - ( 0.025 - max(0, 10.514 - 0.048+0.025))
=6.772

Note: The Operating Income data used here is four times the quarterly (Dec. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

FluoroPharma Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2016  Q: Dec. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.276/( ( (0.009 + max(-4.623, 0)) + (0.007 + max(-4.666, 0)) )/ 2 )
=0.276/( ( 0.009 + 0.007 )/ 2 )
=0.276/0.008
=3,450.00 %

where Working Capital is:

Working Capital(Q: Sep. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.061) - (3.674 + 0.183 + 0.827)
=-4.623

Working Capital(Q: Dec. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.023) - (4.029 + 0.408 + 0.252)
=-4.666

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2016) EBIT data.

3. Operating Income is also linked to Operating Margin %:

FluoroPharma Medical's Operating Margin % for the quarter that ended in Dec. 2016 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2016 )/Revenue (Q: Dec. 2016 )
=-0.521/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

FluoroPharma Medical Operating Income Related Terms

FluoroPharma Medical Operating Income Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Operating Income Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.15 -4.36 -5.17 -3.19 -2.20

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -0.68 -0.68 -0.32 -0.52

FluoroPharma Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-2.20 Mil mean?
FluoroPharma Medical (FPMI) has a Operating Income of $-2.20 Mil as of Dec. 2016. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Operating Income too high?
FluoroPharma Medical's current Operating Income is $-2.20 Mil.
How does FluoroPharma Medical's Operating Income compare to HSTC and OBMPD?
FluoroPharma Medical's Operating Income of $-2.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on FluoroPharma Medical and its competitors. FluoroPharma Medical's current Operating Income is $-2.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Operating Income of $-2.20 Mil. The current Operating Income is $-2.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Operating Income is $-2.20 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.